Pfizer Inc.

LSE:0Q1N Stock Report

Market Cap: US$149.7b

Pfizer Valuation

Is 0Q1N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0Q1N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0Q1N ($26.45) is trading below our estimate of fair value ($79.68)

Significantly Below Fair Value: 0Q1N is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0Q1N?

Key metric: As 0Q1N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0Q1N. This is calculated by dividing 0Q1N's market cap by their current earnings.
What is 0Q1N's PE Ratio?
PE Ratio35x
EarningsUS$4.27b
Market CapUS$149.72b

Price to Earnings Ratio vs Peers

How does 0Q1N's PE Ratio compare to its peers?

The above table shows the PE ratio for 0Q1N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.3x
AZN AstraZeneca
31.3x16.9%UK£162.3b
GSK GSK
21.9x20.5%UK£54.9b
HIK Hikma Pharmaceuticals
19.4x11.0%UK£4.4b
NOVN Novartis
16.6x7.0%CHF 177.3b
0Q1N Pfizer
35x9.5%US$149.7b

Price-To-Earnings vs Peers: 0Q1N is expensive based on its Price-To-Earnings Ratio (35x) compared to the peer average (22.3x).

Price to Earnings Ratio vs Industry

How does 0Q1N's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0Q1N 35.0xIndustry Avg. 19.4xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0Q1N is expensive based on its Price-To-Earnings Ratio (35x) compared to the European Pharmaceuticals industry average (19.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0Q1N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0Q1N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35x
Fair PE Ratio34.1x

Price-To-Earnings vs Fair Ratio: 0Q1N is expensive based on its Price-To-Earnings Ratio (35x) compared to the estimated Fair Price-To-Earnings Ratio (34.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0Q1N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$26.45
US$31.86
+20.5%
14.5%US$45.00US$25.00n/a23
Dec ’25US$26.15
US$32.66
+24.9%
13.8%US$45.00US$25.00n/a23
Nov ’25US$28.55
US$33.41
+17.0%
13.1%US$45.00US$27.00n/a23
Oct ’25US$28.70
US$33.56
+16.9%
13.4%US$45.00US$27.00n/a22
Sep ’25US$28.90
US$33.23
+15.0%
13.0%US$45.00US$27.00n/a22
Aug ’25US$30.40
US$32.87
+8.1%
13.8%US$45.00US$27.00n/a22
Jul ’25US$28.30
US$31.92
+12.8%
15.1%US$45.00US$27.00n/a22
Jun ’25US$28.90
US$31.92
+10.4%
15.1%US$45.00US$27.00n/a22
May ’25US$26.50
US$31.62
+19.3%
15.4%US$45.00US$26.00n/a22
Apr ’25US$27.80
US$32.70
+17.6%
18.6%US$50.00US$26.00n/a22
Mar ’25US$26.60
US$32.71
+23.0%
18.4%US$50.00US$26.00n/a23
Feb ’25US$26.80
US$33.00
+23.2%
19.3%US$50.00US$26.00n/a22
Jan ’25US$28.70
US$33.05
+15.2%
19.9%US$50.00US$23.00n/a22
Dec ’24US$29.10
US$40.41
+38.9%
23.1%US$75.00US$32.00US$26.1522
Nov ’24US$30.70
US$40.91
+33.3%
22.4%US$75.00US$32.00US$28.5522
Oct ’24US$32.90
US$44.41
+35.0%
21.3%US$75.00US$32.00US$28.7022
Sep ’24US$35.90
US$44.27
+23.3%
21.0%US$75.00US$32.00US$28.9023
Aug ’24US$36.30
US$45.69
+25.9%
19.9%US$75.00US$35.00US$30.4023
Jul ’24US$36.30
US$46.31
+27.6%
19.2%US$75.00US$35.00US$28.3022
Jun ’24US$38.00
US$46.68
+22.8%
18.8%US$75.00US$35.00US$28.9022
May ’24US$38.80
US$49.09
+26.5%
16.1%US$75.00US$40.00US$26.5022
Apr ’24US$40.44
US$50.50
+24.9%
16.0%US$75.00US$40.00US$27.8022
Mar ’24US$40.49
US$51.35
+26.8%
15.3%US$75.00US$40.00US$26.6021
Feb ’24US$43.70
US$51.59
+18.1%
15.1%US$75.00US$40.00US$26.8021
Jan ’24US$51.09
US$54.49
+6.7%
12.3%US$75.00US$44.00US$28.7021
Dec ’23US$50.52
US$53.78
+6.5%
12.6%US$75.00US$44.00US$29.1021

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 20:40
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pfizer Inc. is covered by 54 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Kerry HolfordBerenberg
Alistair CampbellBerenberg